Results 241 to 250 of about 1,434,661 (351)

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

open access: yesESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti   +23 more
wiley   +1 more source

Tailoring treatment: dog breed status influences pain assessment and treatment in emergency veterinary care. [PDF]

open access: yesFront Pain Res (Lausanne)
Caddiell RMP   +5 more
europepmc   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

open access: yesESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge   +6 more
wiley   +1 more source

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies

open access: yesESC Heart Failure, EarlyView.
The aim of our study was to develop a more accurate staging system for hereditary ATTR patients currently receiving specific treatment. A staging system was created using as criteria: GLS ≤ −11%, NT‐proBNP ≤ 2,000 ng/L, and eGFR ≤ 65 mL/min. We managed to accurately stratify patients into three disease stages, significantly different in terms of ...
Gabriela Neculae   +7 more
wiley   +1 more source

Circulating oxylipins predict mortality in heart failure with preserved ejection fraction

open access: yesESC Heart Failure, EarlyView.
A targeted LC–MS lipidomics approach identified arterial 15‐keto PGF2a as associated with 5‐year mortality in 90 patients with HFpEF. Abstract Aims Heart failure with preserved ejection fraction (HFpEF) poses significant diagnostic, prognostic and therapeutic challenges, with high morbidity and mortality rates.
Vaishnavi Aradhyula   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy